Research
Hormonal
Patients with type 2 diabetes lose approximately half the weight achieved by non-diabetic patients through dietary counseling, and studies excluding diabetic patients report greater net weight loss.
If you have type 2 diabetes, expect to lose about half as much weight as a non-diabetic person following the same dietary counseling program. This is a known physiological difference, not a failure on your part. Focus on the health benefits of even modest weight loss.
GoodQualifiesMEDIUM confidence
At 3, 6, and 12 months of active intervention, studies of participants with diabetes reported about half the net weight loss as did studies that did not include participants with diabetes (P < 0.001).
Why this rating
Based on meta-analysis of slopes from multiple cohorts, with statistically significant differences.
Source
Meta-analysis: The Effect of Dietary Counseling for Weight Loss
Michael L. Dansinger et al. · Annals of Internal Medicine · 2007
DOI 10.7326/0003-4819-147-1-200707030-00007
Meta-analysis · 46 studiesCited 468×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary counseling interventions produce a modest net weight loss of approximately 2 BMI units (6%) at 12 months compared to usual care, but this benefit diminishes significantly over time as participants regain weight during the maintenance phase.Good
- Among dietary counseling interventions, those that combine diet and exercise result in statistically significantly greater weight loss during the active phase (first year) compared to diet alone, although this difference is not statistically significant during the maintenance phase.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →